Insider · CIK 0001870016
Ramachandran Murali
Files at KAPA (Kairos Pharma, LTD.). First filing Nov 25, 2024, latest Nov 25, 2024.
Ramachandran Murali files SEC Form 4 as officer at KAPA (Kairos Pharma, LTD.). Since Nov 25, 2024, Ramachandran Murali has reported 1 open-market buy worth $318 and 0 open-market sells worth $0, the latest filed on Nov 25, 2024.
A track record needs three past buys with six months of prices behind them; Ramachandran Murali has 0, so none is measured yet.
The newest scored trade: bought $318 of KAPA on Nov 25, 2024, filed Nov 25, 2024, scored 25 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KAPA: Kairos Pharma, LTD.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | KAPA Kairos Pharma, LTD. | AGrant or award COMMON STOCK | +152,672 | $0.00 | $0 | 299,529 | Nov 26, 2025 |
| Jan 1, 2025 | KAPA Kairos Pharma, LTD. | AGrant or award COMMON STOCK | +14,000 | $0.00 | $0 | 147,057 | Feb 24, 2025 |
| Nov 25, 2024 | KAPA Kairos Pharma, LTD. | POpen-market purchase COMMON STOCK | +200 | $1.59 | $318 | 133,057 | Nov 25, 2024 |
Questions about Ramachandran Murali
Answered from the filings on this page, as of the latest one.
Is Ramachandran Murali buying or selling?
Not in the last 12 months. Ramachandran Murali's latest open-market trade on SEC Form 4 was bought $318 of KAPA on Nov 25, 2024.
How did Ramachandran Murali's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ramachandran Murali has 0.
Where does Ramachandran Murali file Form 4?
Ramachandran Murali has filed Form 4 at KAPA (Kairos Pharma, LTD.) as VP of Research and Development. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.